Clinical Trials Logo

Drug Interaction Potential clinical trials

View clinical trials related to Drug Interaction Potential.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03291288 Completed - Clinical trials for Drug Interaction Potential

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Start date: February 26, 2018
Phase: Phase 1
Study type: Interventional

This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents. Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types. In Part 2, the same participants will continue to receive pexidartinib twice daily. Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.